We Want to Use Integrins to
Boost RNAi Medicine
The Shimaoka lab developed I-tsNP, the integrin-targeted stabilized nanoparticle to manipulate gene expression of leukocytes with siRNA in vivo. Our patented technology I-tsNP is designed to solve the major obstacle "delivery problem" that prevents clinical applications of RNAi. I-tsNP enabled us to RE-DISCOVER the well-known cancer therapeutic target cyclin D1 as a novel anti-inflammation target. I-tsNP is a drug delivery platform applicable to broad range of diseases (e.g., inflammation, cancer, infection).
Peer, D., Park, E.J., Morishita, Y., Carman, C.V., Shimaoka, M., "Systemic leukocyte-directed
siRNA delivery revealing cyclin D1 as an anti-inflammatory target" 2008. 319: 627-630
The work is featured in the Science's Perspectives, "The Art of Assembly", The Scientist's Blog, "New drug hopes for RNAi?", and Chemistry World, "RNAi scores victory against Crohn's disease in mice".
Fig. Nano-dimension siRNA delivery carrier, I-tsNP (Left) I-tsNP encapsulates siRNAs (red) inside and directs them to a subset of inflammatory leukocytes via integrin antibody. (Right) The fluorescent image shows that cell-surface bound I-tsNP (green) delivers siRNA (red) to the cytoplasm of leukocytes.
The Shimaoka lab developed I-tsNP, the integrin-targeted stabilized nanoparticle to manipulate gene expression of leukocytes with siRNA in vivo. Our patented technology I-tsNP is designed to solve the major obstacle "delivery problem" that prevents clinical applications of RNAi. I-tsNP enabled us to RE-DISCOVER the well-known cancer therapeutic target cyclin D1 as a novel anti-inflammation target. I-tsNP is a drug delivery platform applicable to broad range of diseases (e.g., inflammation, cancer, infection).
Peer, D., Park, E.J., Morishita, Y., Carman, C.V., Shimaoka, M., "Systemic leukocyte-directed
siRNA delivery revealing cyclin D1 as an anti-inflammatory target" 2008. 319: 627-630
The work is featured in the Science's Perspectives, "The Art of Assembly", The Scientist's Blog, "New drug hopes for RNAi?", and Chemistry World, "RNAi scores victory against Crohn's disease in mice".
Fig. Nano-dimension siRNA delivery carrier, I-tsNP (Left) I-tsNP encapsulates siRNAs (red) inside and directs them to a subset of inflammatory leukocytes via integrin antibody. (Right) The fluorescent image shows that cell-surface bound I-tsNP (green) delivers siRNA (red) to the cytoplasm of leukocytes.
